Evidence map›Paper›PMID 29594819›Full record

Trial reportCancer causes & control : CCC2018

Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Amy Moore, Wen-Yi Huang, Kim Danforth, Roni Falk, Allison Meade, Rachel Bagni, Sonja I Berndt

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer causes & control : CCC, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Amy MooreDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA. amy.moore@nih.gov.ORCID 0000-0002-5083-0577
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Kim DanforthDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Roni FalkDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Allison MeadeProtein Expression Laboratory, Cancer Research and Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Rachel BagniProtein Expression Laboratory, Cancer Research and Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
National Cancer Institute · USProtein Express (United States) · USKaiser Permanente · US

Funding

PLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9M
Etiologic Studies of Prostate CancerZIACP010221 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBANES, DEMETRIUS · 2011 to 2019
$4.1M
Intramural NIH HHS ZIA CP010221
6 · The paper itself

Abstract

backgroundSexually transmitted infections and chronic inflammation have been associated with an increased risk of prostate cancer. Inflammatory mediators, such as cytokines and free radicals, have been hypothesized to play a role.

methodsTo explore the role of inflammation in prostate cancer risk further, we examined the association between pre-diagnostic serum levels of interleukin-16 (IL-16), an important pleiotropic cytokine, and prostate cancer risk among 932 Caucasian cases and 942 controls and 154 African-American cases and 302 controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Serum IL-16 was quantified using enzyme-linked immunoassay. Logistic regression was used to estimate associations between IL-16 and prostate cancer risk, separately by race.

resultsAlthough no association between IL-16 and prostate cancer overall was observed among Caucasians (p = 0.27), a significantly increased risk of high-grade prostate cancer, defined as Gleason ≥ 7 (p

conclusionsThis study found evidence that higher pre-diagnostic IL-16 levels may be associated with increased risk of high-grade disease, supporting inflammation as potential mechanism by which sexually transmitted diseases may increase risk.

Indexed as

AgedBlack or African AmericanCase-Control StudiesColorectal NeoplasmsEarly Detection of CancerFemaleHumansInflammationInterleukin-16Logistic ModelsMaleMiddle AgedOvarian NeoplasmsProspective StudiesProstatic NeoplasmsRisk FactorsInterleukin-16CytokinesInflammationInterleukin-16Prostate cancerRisk factors

Identifiers

PMID29594819
PMCPMC10353757
OpenAlexW2794478820

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.